Tenapanor was originally developed by Ardelyx, and Fosun Pharma obtained the development rights in the Chinese region. It was approved for marketing in the United States in September 2019, launched in Japan in February 2024, and officially launched in China in February 2025.
This product is the world's first intestinal sodium/hydrogen exchanger 3 (NHE3) inhibitor, and also the first intestinal phosphorus absorption inhibitor, with outstanding phosphorus-lowering efficacy and convenient administration. When used in combination with phosphorus binders, it can synergistically enhance the phosphorus-lowering benefit, while greatly reducing the number of daily pills taken by patients and the total volume of medications, significantly alleviating the burden of long-term medication.
With its unique mechanism of action, tenapanor is also expected to address the high incidence of constipation among dialysis patients, boasting outstanding clinical value and making it a highly promising, innovative blockbuster drug in the field of hyperphosphatemia treatment.
1）Intermediate supply
2）Impurity supply
Contact us today for a quote or to discuss your requirements.
